47 related articles for article (PubMed ID: 32672458)
1. Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.
Upadhyay N; Tilekar K; Jänsch N; Schweipert M; Hess JD; Henze Macias L; Mrowka P; Aguilera RJ; Choe JY; Meyer-Almes FJ; Ramaa CS
Bioorg Chem; 2020 Jul; 100():103934. PubMed ID: 32446120
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
3. HDAC8 as an emerging target in drug discovery with special emphasis on medicinal chemistry.
Rajaraman S; Balakrishnan R; Deshmukh D; Ganorkar A; Biswas S; Pulya S; Ghosh B
Future Med Chem; 2023 May; 15(10):885-908. PubMed ID: 37227732
[TBL] [Abstract][Full Text] [Related]
4. Replacement of the hydroxamic acid group in the selective HDAC8 inhibitor PCI-34051.
Long K; Close DA; Johnston PA; Huryn DM
Bioorg Med Chem Lett; 2024 Aug; 108():129810. PubMed ID: 38782078
[TBL] [Abstract][Full Text] [Related]
5. Selection of an improved HDAC8 inhibitor through structure-based drug design.
Vijayakumar B; Umamaheswari A; Puratchikody A; Velmurugan D
Bioinformation; 2011; 7(3):134-41. PubMed ID: 22125384
[TBL] [Abstract][Full Text] [Related]
6. The Importance of Structured Water in HDAC8 for Correct Binding Pose Applied for Drug Design of Anticancer Molecules.
Morales-Herrejón G; Mendoza-Figueroa HL; Martínez-Archundía M; Correa-Basurto J
Anticancer Agents Med Chem; 2024 Jun; ():. PubMed ID: 38835122
[TBL] [Abstract][Full Text] [Related]
7. Design and Evaluation of Nanoscale Materials with Programmed Responsivity towards Epigenetic Enzymes.
Ray P; Sedigh A; Confeld M; Alhalhooly L; Iduoku K; Casanola-Martin GM; Pham-The H; Rasulev B; Choi Y; Yang Z; Mallik S; Quadir M
bioRxiv; 2024 Mar; ():. PubMed ID: 38586020
[TBL] [Abstract][Full Text] [Related]
8. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
Olaoye OO; Watson PR; Nawar N; Geletu M; Sedighi A; Bukhari S; Raouf YS; Manaswiyoungkul P; Erdogan F; Abdeldayem A; Cabral AD; Hassan MM; Toutah K; Shouksmith AE; Gawel JM; Israelian J; Radu TB; Kachhiyapatel N; de Araujo ED; Christianson DW; Gunning PT
J Med Chem; 2021 Mar; 64(5):2691-2704. PubMed ID: 33576627
[TBL] [Abstract][Full Text] [Related]
9. Medicinal chemistry advances in targeting class I histone deacetylases.
Abdallah DI; de Araujo ED; Patel NH; Hasan LS; Moriggl R; Krämer OH; Gunning PT
Explor Target Antitumor Ther; 2023; 4(4):757-779. PubMed ID: 37711592
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of Phthalimide Derivatives and Their Insecticidal Activity against Caribbean Fruit Fly,
Tok F; Yang X; Tabanca N; Koçyiğit-Kaymakçıoğlu B
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830730
[TBL] [Abstract][Full Text] [Related]
11. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
Fontana A; Cursaro I; Carullo G; Gemma S; Butini S; Campiani G
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077415
[TBL] [Abstract][Full Text] [Related]
12. Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Toutah K; Nawar N; Timonen S; Sorger H; Raouf YS; Bukhari S; von Jan J; Ianevski A; Gawel JM; Olaoye OO; Geletu M; Abdeldayem A; Israelian J; Radu TB; Sedighi A; Bhatti MN; Hassan MM; Manaswiyoungkul P; Shouksmith AE; Neubauer HA; de Araujo ED; Aittokallio T; Krämer OH; Moriggl R; Mustjoki S; Herling M; Gunning PT
J Med Chem; 2021 Jun; 64(12):8486-8509. PubMed ID: 34101461
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
[TBL] [Abstract][Full Text] [Related]
14. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
15. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
16. Selective and nonselective HDAC8 inhibitors: a therapeutic patent review.
Adhikari N; Amin SA; Jha T
Pharm Pat Anal; 2018 Nov; 7(6):259-276. PubMed ID: 30632447
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Banerjee S; Adhikari N; Amin SA; Jha T
Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
Hassan MM; Israelian J; Nawar N; Ganda G; Manaswiyoungkul P; Raouf YS; Armstrong D; Sedighi A; Olaoye OO; Erdogan F; Cabral AD; Angeles F; Altintas R; de Araujo ED; Gunning PT
J Med Chem; 2020 Aug; 63(15):8634-8648. PubMed ID: 32672458
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
